Differential expression of circulating miRNAs as a novel tool to assess BAG3-associated familial dilated cardiomyopathy. by Zaragoza Sánchez, Carlos et al.
Bioscience Reports (2019) 39 BSR20180934
https://doi.org/10.1042/BSR20180934
Received: 11 June 2018
Revised: 10 January 2019
Accepted: 25 January 2019
Accepted Manuscript Online:
21 February 2019
Version of Record published:
15 March 2019
Research Article
Differential expression of circulating miRNAs as a
novel tool to assess BAG3-associated familial dilated
cardiomyopathy
Carlos Zaragoza1, Marta Saura2, Ignacio Hernández1, Rafael Ramirez-Carracedo1, Francisco Garcı́a-Garcı́a3,
Jose L. Zamorano4, Alipio Mangas5 and Rocio Toro5
1Cardiology Dept, Univ Francisco de Vitoria, School of Medicine/Hosp Ramón y Cajal Res Unit (IRYCIS), Madrid, Spain; 2Dept of Systems Biology (Physiology), Univ de Alcalá,
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A new familial dilated cardiomyopathy (FDCM) was found related to mutations in BAG3
gene. MicroRNAs (miRNAs) represent new targets of FDCM, although no studies have as-
sessed clinical association between Bcl2-associated athanogene 3 (BAG3)-related DCM
and miRNAs. Here, we studied whether a clinical association between BAG3-related FDCM
and circulating miRNAs may have diagnostic and prognostic value in a small cohort of famil-
ial related individuals carrying a BAG3 mutation (BAG3+) and/or diagnosed of dilated car-
diomyopathy (DCM) (DCM+). The analysis of 1759 circulating miRNAs showed significant
differences between BAG3+ and BAG3- individuals for miRNAs mir-3191-3p, 6769b-3p,
1249-ep, 154-5p, 6855-5p, and 182-5p, while comparisons between BAG3+/DCM+ versus
BAG3+/DCM- were restricted to miRNAs mir-154-5p, 6885-5p, and 182-5p, showing signif-
icant correlation with systolic and diastolic blood pressure, A wave, left atrium length, and
left atrium area. Additionally, when stratified by gender and age, miRNAs were statistically
correlated with critical parameters, including left ventricle ejection fraction (LVEF) and ven-
tricular diameter, in women and young men. Likewise, 56% of BAG3+/DCM+, significantly
co-expressed mir-154-5p and mir-182-5p, and a slight 4% did not express such combi-
nation, suggesting that co-expression of mir-154-5p and mir-182-5p may potentially show
diagnostic value. Further studies will require long-term follow-up, and validation in larger
populations.
Introduction
Bcl2-associated athanogene 3 (BAG3) is a 575 amino acid anti-apoptotic protein that is constitutively
expressed in the heart, skeletal muscle, and some types of cancers. BAG3 works as a co-chaperone wit
Hsc-70 facilitating the removal of misfolded and degraded proteins, and inhibits apoptosis by interacting
with Bcl2 and maintaining the structural integrity of the Z-disk in the muscle [1,2]. Functional studies
revealed that some forms of familial dilated cardiomyopathies (FDCMs) are related to BAG3 mutations
with impaired Z-disc assembly and sensitivity to stress-induced apoptosis [3] proposing that myofibrillar
integrity under mechanical stress is maintained by the complex BAG3–Hsc70, since Hsc70 regulates the
chaperone-dependent E3 ligase CHIP [4,5].
BAG3 mutations related to FDCM were first described in individuals from the same familial group
with diffuse fibrosis and sudden death [6]. The relevance of BAG3 in the etiology of dilated cardiomy-
opathy (DCM) arise from studies in which the levels of BAG3 in the heart of patients with advance heart
failure were significantly reduced, suggesting that BAG3 may represent a critical component to prevent
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heart failure [7]. We have recently identified a rare variant causative of FDCM, detecting a novel frameshift
(p.H243Tfr*64) genetic variation in BAG3 that is segregating in all affected family members, and it correlates with a
severe phenotype of DCM [8].
MicroRNAs (miRNAs) are small non-coding RNA (20–25 nucleotides) that play a key role in gene regulation. In
recent years, miRNAs have emerged as epigenetic regulators in the development and physiology of the cardiovascular
system [9], and deregulation of miRNA expression has been directly associated with the pathophysiology of a large
number of cardiovascular diseases [10,11]. Circulating miRNAs have been studied as mediators in intercellular com-
munication and as potential biomarkers of disease [12,13] including myocardial infarction, coronary artery disease
or heart failure [14,15]. Nevertheless, the role of circulating miRNAs as biomarkers of familial DCM are scarce [16].




The study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki
and its later amendments such as the specific national laws. The study was approved by the ethics committee from
the University Hospital Puerta del Mar, Cádiz, Spain. Written informed consent was obtained from all individuals
included in the study. The study population included 44 BAG3 wild-type patients (20 DCM- and 21 DCM+), and 21
BAG3 mutation carriers (14 DCM+ and 7 DCM-), all of which belonged to the same family to avoid selection bias,
except two independent healthy controls.
Clinical presentation
Detailed clinical data was obtained from each subject, including family history, age of presentation, initial symptoms
of HF, and physical examination, as we described [8]. Diagnostic criteria were evaluated by using 12-lead electrocar-
diogram (ECG), transthoracic echocardiography, tissue Doppler imaging, and ECG-Holter monitoring, when appro-
priate, as previously shown [8]. We have defined phenotypically positive those patients who exhibited left ventricle
ejection fraction (LVEF) levels less than 50% and/or telediastolic left ventricle diameter larger than 55 mm.
Sequencing
About 5 ml of peripheral blood samples were collected in PAXgene RNA tubes and stored at −80 ◦C before use.
Total RNA was isolated using the PZXgene Blood miRNA kit according to manufacturer’s instructions (Quiagen),
and quantified by spectrophotometry (Nanodrop). Quality control and integrity of samples were tested using the
Agilent 2200 tapstation system (Agilent technologies). After that, we generated ultra-sequencing library preparation
solutions with the NEXTflex Small RNA sequencing kit V2 (Bioo Scientific Corp) compatible with Illumina Platforms,
by using 15 cycles of amplification. miRNAs were selected by size (152–154 bp), and sequenced (75 cycles) (Illumina
NextSeq500) with the NextSeq 500/550 High Output Kit v2 (Illumina). Samples were read 50 times/run.
Validation by quantitative real-time PCR (qRT-PCR)
Specific miRNAs were validated by quantitative real-time PCR. First, RNA was reverse transcribed, and the corre-
sponding cDNAs were used as templates in Real Time PCR assays with specific PCR primers for each miRNA by using
the SYBR PCR Master Mix (Thermo Fisher) on a 7900HT Fast Real-Time PCR System (Thermo Fischer). Relative
expression levels were calculated with the 2-ct relative quantification method as previously described [17].
Data analysis
We explored gene expression data by Principal Component Analysis and Clustering methods [18]. We filtered miR-
NAs without counts for all samples. miRNA-Seq data were normalized using Trimmed Mean of M values [19]
and analyzed from the Bioconductor package edgeR [20], fitting a Negative Binomial Generalized Linear Model
where design matrix included one factor for all experimental groups: BAG3-/DCM-, BAG3+/DCM+, BAG3-/DCM+,
BAG3+DCM-. Conventional multiple testing P-value correction procedure proposed by Benjamini–Hochberg was
used to derive adjusted P-values. Clustered heat map was performed as described [21].
The Pearson coefficient of correlation (r) was used to measure the linear correlation between selected miRNAs and
clinical parameters. Only correlations with r > 0.4 with P values < 0.05 were considered.
Receiver Operating Characteristic (ROC) and the area under the ROC curves (AUC) were used to measure the
performance of using combination of selected miRNAs to forecast disease [22].
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Figure 1. Schematic representation of the population study and miRNA distribution
(A and B) Schematic representation of the study design, showing the strategy used to find the corresponding miRNAs of the study.
(C) Clustered heat map of the differentially expressed miRNAs in the population study.
Results
Clinical features of the members included in the study
Our study included a seven-generation Spanish family suffering from familial DCM, as previously reported [8]. A
schematic representation of the study is shown (Figure 1A). Twenty-one members positive for a mutation in BAG3,
were broken down into DCM+ (n=14), or DCM- (n=7) patients, and 44 BAG3 negative mutation carriers (DCM+
(n=21), and DCM-(n=20) (Table 1).
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Table 1 Clinical and echocardiography features from population of the study
BAG3-/DCM-N:20 BAG3-/DCM+N: 21 BAG 3+/DCM+N:14 BAG3+/DCM-N:7
AGE 40.92 +− 15.47 38.86 +− 14.68 45.21 +− 10.00 26.29 +− 17.43
SEX (male%) 10 11 10 3
WEIGHT (kg) 71.29 +− 14.66 74.88 +− 19.13 86.29 +− 15.22 58.00 +− 14.97
HEIGHT (cm) 168.92 +− 10.62 165.96 +− 29.50 174.21 +− 11.97 145 +− 53.52
DYSPHNEA (+) 0 30.1 81.2, P<0.001§ 0
PALPITATIONS (+) 0 32.6 P<0.001‖ 68.8 28.6, P<0.001‖
HR (bpm) 71.92 +− 9.50 87.04 +− 9.79 68.23 +− 11.00 71.33 +− 6.68
SBP (mmHg) 127.42+− 17.02 128.63 +− 13.12 133.08 +− 11.41 121.33 +− 12.06
DBP (mmHg) 70.29 +− 12.41 77.04 +− 10.92 83.22 +− 7.39 76.00 +− 13.43
LVEF (%) 66.81 +− 7.17 45.20 +− 12.40* 47.21 +− 12.00† 57.71 +− 5.64
TDLVD (mm) 48.05 +− 4.68 55.94 +− 8.99 56.98 +− 8.65 47.98 +− 7.86
TSLVD (mm) 32.20 +− 6.17 1437.65 +− 10.26 42.96 +− 10.18 32.40 +− 5.97
TAPSE RV (cm) 21.58 +− 3.12 21.33 +− 3.23 21.35 +− 4.27 21.74 +− 1.22
LA Area (cm2) 17.26 +− 2.31 18.24 +− 4.32 19.80 +− 3.40 15.12 +− 4.50
RA Area (cm2) 13.67 +− 3.04 14.56 +− 3.97 16.11 +− 3.87 12.12 +− 2.91
LA length (mm) 48.02 +− 4.82 52 +− 9.07 60.59 +− 6.03 44.24 +− 4.55‡
RA length (mm) 45.54 +− 7.08 45.99 +− 7.06 52.70 +− 5.35 41.67 +− 5.15
E wave (m/s) 0.79 +− 0.14 0.79 +− 0.18 0.75 +− 0.23 0.86 +− 0.20
A wave (m/s) 0.55 +− 0.25 0.66 +− 0.22 0.70 +− 0.25 0.55 +− 0.14
E/A 1.34 +− 0.39 1.33 +− 0.45 1.14 +− 0.39 1.67 +− 0.60
A septal
Stdi (cm/s) 7.87 +− 1.483 7.82+−1.43 7.5 +− 01.50 8.45 +− 1.11
Etdi 8.72 +− 2.586 9.18+−2.78 8.06 +− 1.64 11.40 +− 3.37
Atdi 7.68 +− 2.609 9.49+−2.11 10.36 +− 1.85 7.72 +− 1.45
A lateral
Stdi 10.40 +− 2.55 10.19 +− 2.46 9.81 +− 2.49 10.94 +− 2.38
Etdi 11.92 +− 4.48 12.90 +− 4.59 11.17 +− 3.23 16.35 +− 5.17
Atdi 9.14 +− 3.03 10.24 +− 2.34 10.18 +− 2.32 10.34 +− 2.58
Fibrosis (+) 0 26.5¶ 62.5 28.6£
Knock (+) 0 30.5 43.8 42.9
BAG3 mutation carriers were divided into phenotypically negative (phenot -) or positive (phenot+) based on the presence of dysphnea and left ventricle
disfunction.
Abbreviations: HR, heart rate; SBP, systolic blood pressure; DAP, dyastolic blood pressure; LVEF, left ventricle ejection fraction; TDLVD, telediastolic
left ventricle diameter; TSLVD, telesistolic left ventricle diameter; TAPSE RV, tricuspid anular plane sistolic exceursion of the right ventricle; LA Area, left
atrium area; RA area, right atrium area; Fibrosis +, presence of fibrosis; Knock +, presence of knock. * P<10−4 LVEF BAG3-/DCM- vs BAG3-/DCM+. †
P<4x10−3 LVEF BAG3-/DCM+ vs BAG3+/DCM+. ‡ P<6x10−3 LA LENGHT BAG3-/DCM+ vs BAG3+/DCM+. § P<0.001 DYSPHNEA BAG3-/DCM+
vs BAG3+/DCM+. ‖ P<0.001 PALPITATIONS BAG3-/DCM+ vs BAG3+/DCM+ AND BAG3+/DCM+ vs BAG3+/DCM-. ¶ P<0.001 PALPITATIONS
BAG3-/DCM+ vs BAG3+/DCM+. £ P<0.001 PALPITATIONS BAG3+/DCM+ vs BAG3+/DCM-.
BAG3-related FDCM is associated with changes in the expression of
circulating miRNAs
To first determine the miRNA profile associated to BAG3 mutation, the analysis of 1759 circulating miRNAs
was performed in BAG3 mutant carriers (BAG3+/DCM+ and BAG3+/DCM-) and BAG3 wild-type individuals
(BAG-/DCM+ and BAG3-/DCM-). By applying a criterion of 2-fold difference in the expression between groups,
mir-3191-3p, -6769b-3p, -1249-ep, -154-5p, -6855-5p, and -182-5p were increased in BAG3+ mutant carriers (Figure
1C). A further analysis between BAG3-associated DCM (BAG3+/DCM+) versus BAG3 asymptomatic patients
(BAG3+/DCM-) revealed no differences between miRNAs mir-3191-3p, 6769b-3p, and 1249-ep, while the levels
of miRNAs mir-6855-5p, 182-5p, and 154-5p discriminated BAG3 symptomatic DCM versus BAG3 asymptomatic
DCM patients (Figure 1B), as also shown when plotted the selected three miRNAs in a clustered heat map (Figure
1C).
A more detailed analysis did show a significant increase of main mir-154-5p and mir-182-5p levels (4.5 and 1.4
times, respectively) in BAG3+/DCM+ individuals (Figure 2A: BAG3+/DCM+ (DCM) vs BAG3+/DCM- (Control)),
while mir-6855-5p was 2.3 times overexpressed in BAG3+/DCM- patients (Figure 2A). By contrast, no significant
4 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 2. Expression of selected miRNAs in the population study
(A) Differential expression of mir-154-5p (left), mir-182-5p (middle), and mir-6855-5p (right) in BAG3+/DCM+ patients (DCM)
compared with asymptomatic BAG3+/DCM- individuals (Control). (Mean +− SD, *P<0.05 mir-154-5p DCM vs Control. *P<0.01
mir-182-5p DCM versus Control. *P<0.01 mir-6855-5p DCM versus Control). (B) Differential expression of mir-154-5p, mir-182-5p,
and mir-6855-5p in males (M) and females (F) BAG3+/DCM+ patients (DCM) compared with males (M) and females (F) BAG3+/DCM-
individuals (C)). (n=21 Mean +− SD). (C) Differential expression of mir-154-5p, mir-182-5p, and mir-6855-5p between males and fe-
males with decreased LEVF (LVEF<50%).
differences were found in the main expression of the same miRNAs in BAG3-/DCM+ versus BAG3-/DCM- indi-
viduals (mir-154-5p P: 0.9263; mir-182-5p P:0.403; mir-6855-5p P: 0.468). No gender differences were detected be-
tween DCM+ and DCM- patients, and the same applies when comparing clinical parameters, including LVEF (<50%:
DCM+) (Figure 2B,C, respectively). Taken together, our data suggest that miRNAs mir-154-5p, -182-5p, and -6855-5p
are specific of this type of FDCM.
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Table 2 Pearson’s correlation coefficient between selected miRNAs and clinical parameters
mir-6855-5p mir-154-5p mir-182-5p
SBP r = −0.60592/P<0.006 r = −0.26238/P:0.291 r = −0.32274/P:0.1894
DBP r = −0.44933/P<0.05 r = −0.23790/P:0.340 r = −0.17245/P:0.4926
AOD r = −0.47179/P<0.05 r = −0.05152/P:0.8291 r = −0.24271/P:0.3017
LAL r = −0.73897/P<0.0002 r = −0.10632/P:0.6552 r = −0.14169/P:0.5283
LAA r = 0.44648/P<0.05 r = −0.4176/P:0.073 r = −0.31634/P:0.1811
AW r = −0.40383/P:0.07 r = 0.11519/P<0.6283 r = 0.49081/P<0.05
Table 3 Pearson’s correlation coefficient between selected miRNAs and clinical parameters
mir-6855-5p mir-154-5p mir-182-5p
FEMALE
LVEF r = 0.81513/ P<0.001 r = −0.21378/ P:0.1354 r = 0.8942/P<0.04
TDLVD r = −0.9853/P<0.001 r = 0.18190/ P:0.08 r = −0.08267/P:0.364
TSLVD r = −0.9859/P<0.02 r = 0.9952/P<0.001 r = −0.91862, P:0.06
MALE
LVEF r = −0.0470/P:0.08 r = 0.38182/P:0.08 r = 0.8710/P<0.04
TDLVD r = −0.9970/P<0.04 r = −0.37954/P:0.11 r = −0.32413/P:0.163
TSLVD r = 0.28112/P:0.06 r = −0.36242/ P:0.665 r = −0.359/P:
Association between BAG3-mediated DCM circulating miRNAs and
severity of disease
We compared selected miRNA expression levels with the clinical parameters of the study (Table 1). When data were
not stratified, negative correlations between systolic (r = −6059, P<0.006) and diastolic blood pressure (r = −4493,
P<0.05), aortic diameter (r = −0.47179, P<0.003), left atrium length (r = −0.73897 P<0.0002), and left atrium area
(r = 0.44648, P<0.05) with mir-6855-5p; and a positive correlation between A wave and mir-182-5p (r = 0.4908,
P<0.002) were detected (Table 2). However, no statistical correlations were found between selected miRNAs and
clinical prognostic parameters of disease, including LVEF or systolic and diastolic ventricular diameters (TDLVD,
TSLVD).
The data shown above, lead us to investigate BAG3 associated DCM by gender and age stratification. Although the
study did not show sex differences in the main levels of selected miRNAs (Figure 2B,C), when performing correlation
analysis, positive statistical correlation in women BAG3+/DCM+ between LVEF, TDLVD, and TSLVD with selected
miRNAs were detected (Table 3). By contrast, correlations were restricted to TDLVD with hsa-mir-6855-5p, and to
LVEF with hsa-mir-182-5p in men younger than 40 years of age (Table 3). Besides, BAG3+/DCM- men or women did
not show any statistical correlation between selected miRNAs and the clinical parameters of the study. Taken together
these results suggest that selected miRNAs may forecast BAG3 associated FDCM between men and women.
The panel of mir-154-5p and mir-182-5p may forecast DCM in BAG3
mutant carriers
To further study the potential use of selected miRNAs as diagnostic tools, we compared the number of BAG3+/DCM+
patients, and healthy controls expressing a combination of two (double+) or three miRNAs. We found no differ-
ences between individuals co-expressing mir-154-5p and mir-6855-5p, neither subjects co-expressing mir-6855-5p
and mir-182-5p (Figure 3A,B). By contrast, 56% of BAG3+/DCM+ individuals, significantly co-expressed both
mir-154-5p and mir-182-5p, and a slight 4% did not, whereas on the opposite, no BAG3+/DCM- individuals
co-expressed both miRNAs and 28% of them did not express any miRNA (double-) (Figure 3C), suggesting that
the combination of mir-154-5p and mir-182-5p may potentially have diagnostic value.
We used a ROC curve to test the accuracy of the results measured by the AUC to analyze co-expression of
mir-6855-5p and mir-154-5p (Figure 4A), mir-6855-5p and mir-182-5p (Figure 4B), or mir-154-5p and mir-182-5p
(Figure 4C), detecting a 74% accuracy (AUC), and a 84.6% sensitivity when using co-expression of mir-154-5p and
mir-182-5p in BAG3/DCM patients (Figure 4C). Nevertheless, additional studies aimed to increase sample size should
be performed for further validation.
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Figure 3. Co-expression of selected miRNAs in the population study
Percentage of BAG3+DCM-(Control) or BAG3+DCM+ (DCM) subjects, co-expressing two selected miRNAs (A)
mir-154-5p/mir-6855-5p. (B) mir-6855-5p/mir-182-5p. (C) mir-154-5p/mir-182-5p. n=20, Mean +− SD. *P<0.01 Double +
mir-154-5p/mir-182-5p DCM versus Control. $P<0.01 Double - mir-154-5p/mir-182-5p DCM versus Control.
Figure 4. Receiver operating characteristic (ROC) curves to test accuracy of selected miRNAs in the population study
Diagnostic sensitivity and specificity of using the combination of mir-6855/mir-154 (A) mir-6855/mir-182 (B) and mir-154/mir-182
(C) delimited by ROC/AUC analysis.
Discussion
In the present study, we currently report the differential expression of selected miRNAs in BAG3 deletion carriers from
a small cohort of Spanish familial individuals with DCM. Among the 1759 miRNAs analyzed, significant differences
between BAG3 mutants versus BAG3 wild-type individuals were found for mir-3191-3p, mir-6769b-3p, mir-1249-ep,
mir-154-5p, mir-6855-5p, and mir-182-5p. Interestingly, DCM patients expressing BAG3 mutation differentially ex-
pressed mir-154-5p, mir-6855-5p, and mir-182-5p, when compared with asymptomatic BAG3 mutation carriers. The
expression of selected miRNAs correlated with several parameters of disease, including blood pressure, left atrium
area and length, while sex and age differences were found associated between selected miRNAs and diagnostic DCM
parameters, including LVEF, TDLVD, and TSLVD. The combination of mir-154-5p and mir-182-5p, may have a pre-
dictive value of disease, since almost a 60% of BAG3+/DCM+ patients, co-expressed mir-154-5p and mir-182-5p,
while a slight 4% did not expressed any miRNA.
Familial DCM counts for more that 50% of all cases reported of DCM, and most of them are associated with genetic
variations of single genes including, ACTC1, RBM20, MYBPC3, MYH6, MYH7, TNNT2, TPM1, SCN5A, FHOD3,
SLC39A8, MLIP, ALPK3, or BAG3 [2,22]. However, the transition between single point mutations and DCM still
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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require further investigation. We and others have reported the relevance of BAG3 in the onset and progression of
DCM [1,7,8,24,25,26]. BAG3 regulates myocyte contraction through interaction with L-type calcium channels [27],
thus BAG3 mutations have been associated with different forms of familial cardiomyopathy, including DCM. Here,
we provide new evidence which may help to explain the effect of BAG3 on DCM, by regulating the levels of selected
miRNAs.
The implication of circulating miRNAs in the pathogenesis and progression of DCM in mice and in humans is
well documented. Down-regulation of mir-1, mir-669a, mir-451a, and up-regulation of mir-3135b, mir-3908 and
mir-5571-5p are related with DCM progression [20,28]. Recently it was found a correlation between the time by
which selected miRNAs are expressed and beta-blocker administration induces reverse remodeling in DCM patients
[29], but the relationship between BAG3-mutation carriers with DCM and the expression profile of miRNAs remains
unknown. Here, we show that DCM patients carrying a BAG3-mutation show differential expression of mir-6855-5p,
mir-182-5p, and mir-154-5p.
miRNA mir-182 family members play a role in cardiovascular disease, including myocyte hypertrophy [30], heart
failure [31], and cardiac allograft rejection [32,33]. On the other hand, mir-154 inhibition reduces cardiac fibrosis,
cardiac myocyte size, and cardiac dysfunction [34]. With regard to the expression of mir-6855-5p, we describe here
for the first time the relationship between BAG3-mutation carriers with DCM and systolic (r = −6059, P<0.006),
diastolic blood pressure (r = −4493, P<0.05), aortic diameter (r = −0.47179, P<0.003), left atrium length (r =
−0.73897, P<0.0002), and left atrium area (r = 0.44648, P<0.05). Interestingly, we found sex differences in the
relationship between mir-6855-5p with LVEF (r = 0.81513, P<0.001), TELVD (r = −0.9853, P<0.001), and TSLVD
(r = −0.9859, P<0.02) in women, while in men mir-6855-5p statistical correlation was restricted to TDLVD (r =
−0.9970, P<0.04).
Targets of mir-182-5p may include genes encoding for several transcription factors, cell cycle regulators and
apoptosis related proteins, including Bcl2 [35]. As part of the mechanism induced to prevent heart failure and is-
chemia/reperfusion damage, BAG3 promotes cell survival through binding to several proteins including hsp70 and
Bcl2 [36]. In DCM BAG3-mutation carriers, the levels of mir-182-5p resulted significantly elevated respect to asymp-
tomatic patients, and correlated with LVEF both in men and women, suggesting that lack of mir-182-5p expression
may be related with the antiapoptotic effect of BAG3 in the heart, as others reported in mice overexpressing BAG3,
and subjected to myocardial infarction, showing improved left ventricular function, and reduced hypoxia-induced
cardiomyocyte apoptosis [37].
Statistical correlation was found between mir-154-5p and TSLVD in DCM female BAG3+ patients. Important
targets of mir-154-5p may include Dicer, which on its absence induces significant DCM in mice, and is consider-
ably abundant in patients with LV assistant devices to improve cardiac function [25]. Other targets may also include
Wnt11, in which mir-154-5p targets Wnt11 during osteogenic differentiation [32] and improves cardiac function in
Coxsackievirus induced myocarditis [38], and DiGeorge syndrome [33], but the specific role of mir-154-5p on Wnt11
in DCM is still unknown.
Almost 60% of BAG3+/DCM+ patients co-expressed a combination of mir-182-5p, and mir-154-5p, and
ROC/AUC analysis evidenced a significant level of confidence and accuracy. Considering the significant limitations
of the study (reduced sample size, lack of follow-up analysis of patients and lack of miRNA derived target genes), our
data suggest that the combination of mir-154-5p and mir-182-5p may potentially have diagnostic value of FDCM.
Average age of BAG3+/DCM- group patients was 26 years old, another significant limitation of the study. Therefore,
further analyses focused to reduce the above limitations, will shed light about future diagnostic value of selected
miRNAs found in the present study.
Summary
• The culprit genes underlying the pathogenesis of more than 50% of familial DCM are still unknown.
• A new FDCM associated to mutation in the BAG3 gene was detected. DCM positive family mem-
bers differentially express selected miRNAs depending on BAG3 expression. Statistical correlations
between selected miRNAs and DCM critical parameters were found.
• Our data suggest that the combination of selected miRNAs may potentially have a diagnostic value
of FDCM. Considering the significant limitations of the study (reduced sample size, lack of follow-up
8 © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
License 4.0 (CC BY).
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analysis of patients and lack of miRNA derived target genes), further investigations focused to reduce
the above limitations will shed light about implementation in the population.
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